speckle tracking mode of the stress ECHO test with dobutamine
Otherspeckle tracking mode of the stress ECHO test with dobutamine
NCT Number: NCT05210465
METHOD is a prospective observational program that will be conducted in 1centre of the Russian Federation. Prospective follow-up will be for about 6 months. The METHOD study is a 2 visit study with first visit of inclusion and second visit of completion of the study. Patients with stable angina pectoris eligible to the study inclusion criteria will be invited to participate in this observational program. The parameters for analysis will be collected by doctors and entered into CRF. The final analysis will include data from patients who were taking TMZ 80 mg OD during the observational period. The decision to stop the study will be made once 36 patients receiving treatment with trimetazidine 80 mg OD will have been evaluated at V1.
It is expected that 5 cardiologists will participate in the program. The planned number of patients is 36.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
"Institute for Complex Issues of Cardiovascular Diseases", Kemerovo, Russia
To describe antiischemic and antianginal effectiveness of trimetazidine OD 80 mg as well as adherence to the treatment with TMZ 80 mg OD in patients with stable angina pectoris and prior MI in real clinical practice in Russia
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
speckle tracking mode of the stress ECHO test with dobutamine
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Servier Russia
Industry
Acronym: METHOD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01658683
Arterial Occlusive Diseases, Arteriosclerosis
Ottawa, Ontario, Canada
View Trial DetailsNCT03253692
Arterial Occlusive Diseases, Arteriosclerosis
Lexington, Kentucky, United States
View Trial DetailsNCT07763769
Angina Pectoris, Angina, Stable
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05336435
Acute Coronary Syndrome, Angina Pectoris
Aabenraa, Denmark
View Trial Details